For Immediate Release:
September 28, 2016

Media Contact:
Katie Kiley Brown, NCCN
215-690-0238
brown@nccn.org

NCCN Congress to Explore Complex Issues in Treating Hematologic Malignancies

The NCCN 11th Annual Congress: Hematologic Malignancies™ returns to New York City September 30 – October 1, 2016; registration is still open at NCCN.org/HEM

FORT WASHINGTON, PA — On Friday, September 30, and Saturday, October 1, 2016, more than 600 clinicians will attend the National Comprehensive Cancer Network® (NCCN®) 11th Annual Congress: Hematologic Malignancies™ at the New York Marriott Marquis in New York City.

Moderated by Ranjana H. Advani, MD, Stanford Cancer Institute, and Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center, the 2016 congress features sessions focused on issues related to pathology, transplantation, and various new therapies in the treatment of hematologic malignancies.

Friday’s sessions open with a discussion of the evolving management of Myeloproliferative Neoplasms (MPN), which will feature the new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for MPN published this week. In addition, NCCN Guidelines® panel members will discuss treatment approaches in Chronic Myelogenous Leukemia (CML) and Acute Myeloid Leukemia (AML), and a panel of experts will present and deliberate challenging patient case studies.

On Saturday, there are 12 sessions that include patient cases in a variety of hematologic malignancies, as well as explore treatment advances in T-Cell Lymphomas, Diffuse Large B-Cell Lymphoma, Multiple Myeloma, and Acute Lymphoblastic Leukemia. Experts will also discuss best practices for supportive care and shared decision-making. A debate of the controversies in front-line management of Chronic Lymphocytic Leukemia (chemo-immunotherapy vs. continuous TKI therapy) will close this year’s congress.

Attendees also have the opportunity to attend a complimentary lunch symposium: The Future of Targeted Therapies for AML. This session is presented by NCCN and PRIME® Education, Inc. The full agenda and registration information is available at NCCN.org/HEM.
NCCN Congress to Explore Complex Issues in Treating Hematologic Malignancies

The NCCN 11th Annual Congress: Hematologic Malignancies™ is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies. This congress is designated for AMA PRA Category 1 Credit™ and is certified for credit for nurses and pharmacists.

###

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news.